Louis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that sits behind the process of individualised cell therapy – and why team cult
Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy. Updated results from the ZUM